Oxaliplatin-induced peripheral neuropathy
Conditions
Interventions
case series:none
Sponsors
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. All the selected cases were in accordance with the diagnostic criteria of colorectal cancer in the ‘’Norms for the Diagnosis and Treatment of Common Malignant Tumors in China’’ of the Ministry of Health, and had been confirmed by pathology; 2. For patients with stage II-III adjuvant chemotherapy after radical resection of colorectal cancer, chemotherapy regimen was mFOLFOX6 or XELOX; 3. The predicted survival time of patients with Cartesian score above 60 is more than 6 months; 4. Patients aged 18-85 years; 5. Patients without serious damage to the heart, liver, kidney or hematopoietic system, or with abnormalities but after symptomatic treatment (such as white, platelet, liver protection, etc.) meet the inclusion requirements: (1) Hemoglobin (HGB)>=90g/L, or >=90g/L after hemoglobin infusion; (2) Absolute neutrophil count (ANC) >=1.5x10^9/L; (3) Platelet (PLT)>=75x10^9/L; (4) Liver function: ALT and AST=30g/L; (7) Serum creatinine <1.5 times the normal upper limit.
Exclusion criteria
Exclusion criteria: 1. Present peripheral neuropathy of any grade; 2. Previous treatment with neurotoxic chemotherapeutic agents, such as oxaliplatin, cisplatin, taxanes or vinca alkaloids; 3. Participate in any other clinical studies; 4. A family history of hereditary/familial peripheral neuropathy; 5. Patients with mental illness who cannot cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NCI-CTCAE4.0 neurotoxicity grading; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of chemotherapy cycles;Duration of neurotoxicity; | — |
Countries
China
Contacts
Public ContactHuo Jiege
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Outcome results
None listed